Cardiac defects in spinal muscular atrophy and the role of SMN in cardiomyocyte homeostasis

This study demonstrates that spinal muscular atrophy involves significant cardiac pathology characterized by structural abnormalities and cardiomyocyte-intrinsic metabolic shifts driven by SMN deficiency-induced upregulation of PTEN signaling.

The Gist

Imagine the human body as a highly sophisticated city. In this city, there is a specific protein called SMN (Survival Motor Neuron). Think of SMN as the city's master electrician and maintenance crew. Its main job is to keep the power lines (nerves) running so the muscles can move.

For a long time, doctors thought that if the electrician (SMN) was missing, only the power lines (nerves) and the buildings they served (muscles) would suffer. The rest of the city, including the heart, was thought to be safe because it had its own backup generators.

However, this new study suggests that the heart is actually part of the same maintenance crew. When the electrician is missing, the heart's own internal systems start to glitch, even if the heart is still beating.

Here is a breakdown of what the researchers found, using simple analogies:

1. The Heart is Not Just a Bystander

The researchers looked at the hearts of 14 children who had a severe form of a disease called Spinal Muscular Atrophy (SMA). These children passed away before modern treatments were available.

• The Finding: While some hearts looked perfectly normal, others showed signs of trouble.
• The Analogy: Imagine checking the engines of cars in a fleet. Most engines look fine on the outside. But when you pop the hood, you find that some have rusty pipes (fibrosis), some are filled with too much grease (fat deposits), and a few are actually too heavy (enlarged) for their size.
• The Takeaway: The heart isn't just "working hard" because the muscles are weak; the heart itself is struggling with its own internal maintenance issues.

2. The Heart's Energy Crisis

To understand why the heart was struggling, the scientists took healthy human heart cells in a lab and turned off the "SMN switch" to see what happened.

• The Finding: When SMN was missing, the heart cells didn't run out of energy. Instead, they changed how they made energy. They stopped using their "quick-burn" fuel (sugar/glycolysis) and switched almost entirely to their "slow-burn" fuel (oxygen/mitochondria).
• The Analogy: Imagine a car that usually runs on a mix of gasoline and electric battery. Suddenly, the electric system fails. The car doesn't stop; it switches to running 100% on gasoline. It keeps moving, but the engine is running hotter and working harder than it should. It's a compensatory shift, not a total failure, but it puts stress on the engine over time.

3. The "Brake" That Got Stuck (PTEN)

The most exciting discovery was about a specific molecule called PTEN. In our city analogy, think of PTEN as a brake pedal that controls how fast the heart cells grow and divide.

• The Finding: When SMN was missing, the "brake" (PTEN) got stuck in the "ON" position in the heart cells. This happened in the lab cells, in the hearts of the children, and in a mouse model of the disease.
• The Twist: This stuck brake was most noticeable in very young hearts (babies and young children). As the mice got older and the disease progressed, the brake seemed to loosen up again.
• The Analogy: It's like a child learning to ride a bike. If the training wheels (SMN) are missing, the child (the heart) might panic and slam on the brakes (PTEN) to stay safe. But as the child grows older and the bike changes, they might learn to ride differently, and the panic-braking stops. This suggests that the heart is most vulnerable to SMN deficiency during its early development.

4. Why This Matters Today

Today, we have amazing new medicines (like gene therapies) that fix the SMN problem. These drugs are like hiring a super-electrician to fix the power lines.

• The Problem: These new drugs are great at fixing the nerves and muscles, but they might not reach the heart in the same way. Some drugs go straight to the brain and spinal cord (intrathecal), while others go everywhere in the body (systemic).
• The Warning: If the "super-electrician" fixes the nerves but leaves the heart's internal "brake" (PTEN) stuck or its energy mix unbalanced, patients might live longer but still develop heart problems later in life.

The Bottom Line

This paper tells us that SMA is a whole-body disease, not just a muscle disease.

The heart is like a sensitive engine that relies on the same maintenance crew (SMN) as the muscles. When that crew is missing, the heart tries to adapt by changing its fuel source and slamming on its brakes. While modern medicine is saving lives, we need to make sure we are also checking the "engine" (the heart) to ensure it doesn't wear out from these hidden stresses as patients live longer.

In short: We fixed the power lines, but we need to make sure the heart's internal wiring is also getting the maintenance it needs.

Technical Summary

1. Problem Statement

Spinal Muscular Atrophy (SMA) is a genetic neuromuscular disorder caused by the deficiency of the Survival Motor Neuron (SMN) protein, primarily characterized by motor neuron degeneration and muscle atrophy. While recent disease-modifying therapies (e.g., nusinersen, onasemnogene abeparvovec, risdiplam) have significantly improved motor outcomes and survival, SMA is increasingly recognized as a systemic disease.

• The Gap: There is limited understanding of the intrinsic cardiac pathology in SMA, particularly in the pre-treatment era. It remains unclear whether cardiac dysfunction is solely a secondary consequence of immobility and respiratory failure or if SMN deficiency directly impacts cardiomyocyte homeostasis.
• Objective: To characterize the spectrum of cardiac pathology in untreated SMA Type 1 patients and to elucidate the cell-autonomous mechanisms by which SMN deficiency alters cardiomyocyte metabolism and gene expression.

2. Methodology

The study employed a multi-level approach combining human postmortem analysis, in vitro human cell models, and in vivo mouse models.

• Human Postmortem Cohort:

  • Subjects: 14 pediatric patients with genetically confirmed SMA Type 1 (pre-treatment era).
  • Data: Comprehensive gross anatomical, histopathological (H&E, Masson's Trichrome), and clinical data were analyzed.
  • Controls: Age- and sex-matched control tissues were obtained from the NIH Neurobiobank.
  • Analysis: Pathologists reviewed slides for fibrosis, fat deposition, and structural abnormalities. Immunoblotting was performed on 7 frozen SMA cardiac samples to assess PTEN protein levels.

• In Vitro Cellular Models:

  • Cells: Differentiated human induced pluripotent stem cell (iPSC)-derived cardiomyocytes and primary human skeletal myotubes.
  • Intervention: SMN knockdown (KD) was achieved using AAV2 vectors expressing siRNA (cardiomyocytes) or Lipofectamine-mediated transfection (myotubes).
  • Assays:
    • Metabolic Flux: Seahorse XF assays to measure Oxygen Consumption Rate (OCR), Extracellular Acidification Rate (ECAR), and ATP production sources.
    • Transcriptomics: Gene expression microarrays (Clariom S Assay) followed by pathway enrichment analysis.

• In Vivo Mouse Model:

  • Model: Smn2B/− mice (severe SMA model) vs. Smn2B/+ littermate controls.
  • Timepoints: Cardiac tissue collected at Postnatal Day 9 (P9, early stage) and Postnatal Day 19 (P19, symptomatic stage).
  • Analysis: Immunoblotting to quantify SMN and PTEN protein levels across developmental stages.

3. Key Contributions

• First Detailed Autopsy Series: Provides the first comprehensive description of gross and microscopic cardiac pathology in a cohort of untreated SMA Type 1 patients, moving beyond anecdotal case reports.
• Cell-Autonomous Mechanism: Demonstrates that SMN deficiency directly alters cardiomyocyte metabolism and gene expression, independent of neuromuscular failure.
• Identification of PTEN as a Key Pathway: Identifies PTEN signaling as a specific, upregulated pathway in SMN-deficient cardiomyocytes, linking it to developmental stages and human pathology.
• Metabolic Reprogramming: Characterizes a specific metabolic shift in SMN-deficient cardiomyocytes from glycolysis toward oxidative phosphorylation as a compensatory mechanism.

4. Key Results

A. Human Postmortem Findings (Heterogeneous Pathology)

• Gross Anatomy: While most hearts appeared normal, a subset showed cardiomegaly (increased heart mass) disproportionate to body weight. One patient exhibited fatty replacement of the ventricular tissue resembling Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC).
• Microscopic Pathology: Even in "structurally normal" hearts, subtle abnormalities were prevalent:
  • Interstitial Fibrosis: Present in 58% (7/12) of cases.
  • Fat Deposition: Excess perivascular or intracardiac fat was found in 58% (7/12) of cases, with one case showing significant fat infiltration into both ventricles.
• Clinical Correlation: These findings occurred in patients with varying degrees of immobility, suggesting the pathology is not solely due to inactivity.

B. In Vitro Cardiomyocyte Mechanisms

• Metabolic Shift: SMN knockdown in human cardiomyocytes caused:
  • Increased baseline Oxygen Consumption Rate (OCR).
  • Decreased Extracellular Acidification Rate (ECAR).
  • A shift from glycolytic ATP production to mitochondrial oxidative phosphorylation.
  • Crucially: Total ATP production remained unchanged, indicating a compensatory metabolic redistribution rather than bioenergetic failure.
• Transcriptomic Dysregulation: SMN KD resulted in >1,000 differentially expressed genes (mostly downregulated).
  • Pathway Analysis: PTEN signaling was the only pathway showing a positive activation score (upregulation).
  • Specificity: Parallel experiments in skeletal myotubes showed minimal transcriptional changes, highlighting that cardiomyocytes are uniquely sensitive to SMN loss compared to skeletal muscle.

C. In Vivo Mouse Model & PTEN Validation

• PTEN Expression in Humans: Immunoblotting of human SMA hearts revealed elevated PTEN protein levels in a subset of patients (3/7), particularly in the youngest (4 months) and oldest (16 years) patients.
• PTEN Expression in Mice:
  • At P9 (early postnatal, high SMN levels): Smn2B/− mice showed significantly elevated PTEN levels compared to controls.
  • At P19 (symptomatic, low SMN levels): PTEN levels normalized, showing no significant difference from controls.
• Conclusion: PTEN upregulation is a stage-dependent phenomenon, most prominent during early cardiac development when SMN is critical for signaling thresholds.

5. Significance and Implications

• Heart as a Primary Target: The study confirms the heart is a biologically relevant target of SMN deficiency, exhibiting intrinsic metabolic and transcriptional vulnerabilities.
• Therapeutic Era Considerations: As SMA patients live longer due to new therapies, cardiac complications may emerge as a limiting factor.
  • Biodistribution Matters: Systemic therapies (e.g., risdiplam, IV Zolgensma) may offer better cardiac protection than intrathecal therapies (CNS-targeted), which might leave peripheral tissues like the heart vulnerable to residual SMN deficiency.
• PTEN as a Biomarker and Target: The identification of PTEN upregulation suggests it could serve as an early biomarker for cardiac stress in SMA. Furthermore, since PTEN suppression has been shown to ameliorate SMA severity in mice, modulating PTEN signaling (carefully, given its role as a tumor suppressor) could be a future adjunctive strategy for cardiac protection.
• Future Directions: The authors call for prospective studies in treated cohorts incorporating cardiac phenotyping (ECG, MRI, strain imaging) and monitoring of metabolic/PTEN biomarkers to define long-term cardiac risks.

In summary, this paper bridges the gap between clinical observation and molecular mechanism, establishing that SMN deficiency causes direct, stage-dependent cardiac dysfunction mediated by metabolic shifts and PTEN signaling dysregulation.